Rodin Therapeutics: Struggling Alkermes spends $950M sculpting Rodin buyout
Just a month ago, Alkermes was announcing it was slashing scores of jobs; now, it's willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.
Read full article »
Rodin is a biotechnology company that discovers, develops and commercializes therapeutics for the treatment of neurologic diseases.
Read more